JP2021513974A - Ｉｌ−５／ｉｌ−５ｒ、及び、ｉｌ−４／ｉｌ−４ｒ又はｉｌ−１３／ｉｌ−１３ｒに対する組合せアンタゴニスト - Google Patents
Ｉｌ−５／ｉｌ−５ｒ、及び、ｉｌ−４／ｉｌ−４ｒ又はｉｌ−１３／ｉｌ−１３ｒに対する組合せアンタゴニスト Download PDFInfo
- Publication number
- JP2021513974A JP2021513974A JP2020543512A JP2020543512A JP2021513974A JP 2021513974 A JP2021513974 A JP 2021513974A JP 2020543512 A JP2020543512 A JP 2020543512A JP 2020543512 A JP2020543512 A JP 2020543512A JP 2021513974 A JP2021513974 A JP 2021513974A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- domain
- acid sequence
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000005557 antagonist Substances 0.000 title claims abstract description 186
- 102000003816 Interleukin-13 Human genes 0.000 title claims abstract description 78
- 108090000176 Interleukin-13 Proteins 0.000 title claims abstract description 77
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 title claims abstract description 44
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 title claims abstract description 39
- 108040003607 interleukin-13 receptor activity proteins Proteins 0.000 title claims abstract description 39
- 108010002616 Interleukin-5 Proteins 0.000 title claims abstract description 32
- 108090000978 Interleukin-4 Proteins 0.000 title claims abstract description 14
- 108040006859 interleukin-5 receptor activity proteins Proteins 0.000 title claims abstract 7
- 230000027455 binding Effects 0.000 claims abstract description 190
- 238000009739 binding Methods 0.000 claims abstract description 167
- 239000000427 antigen Substances 0.000 claims abstract description 160
- 108091007433 antigens Proteins 0.000 claims abstract description 160
- 102000036639 antigens Human genes 0.000 claims abstract description 160
- 208000006673 asthma Diseases 0.000 claims abstract description 118
- 238000011282 treatment Methods 0.000 claims abstract description 84
- 230000001684 chronic effect Effects 0.000 claims abstract description 70
- 208000023504 respiratory system disease Diseases 0.000 claims abstract description 66
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 312
- 210000004027 cell Anatomy 0.000 claims description 69
- 238000000034 method Methods 0.000 claims description 69
- 239000012634 fragment Substances 0.000 claims description 50
- 238000006467 substitution reaction Methods 0.000 claims description 47
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 claims description 34
- 102000000743 Interleukin-5 Human genes 0.000 claims description 28
- 230000019491 signal transduction Effects 0.000 claims description 26
- 241000282836 Camelus dromedarius Species 0.000 claims description 24
- 210000004602 germ cell Anatomy 0.000 claims description 22
- 230000002829 reductive effect Effects 0.000 claims description 21
- 230000002378 acidificating effect Effects 0.000 claims description 19
- 230000007935 neutral effect Effects 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 16
- 210000002175 goblet cell Anatomy 0.000 claims description 16
- 206010054949 Metaplasia Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 230000015689 metaplastic ossification Effects 0.000 claims description 14
- 206010009137 Chronic sinusitis Diseases 0.000 claims description 13
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 claims description 13
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 13
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 12
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 12
- 102000004388 Interleukin-4 Human genes 0.000 claims description 12
- 230000003843 mucus production Effects 0.000 claims description 12
- 101000960969 Homo sapiens Interleukin-5 Proteins 0.000 claims description 11
- 229940124597 therapeutic agent Drugs 0.000 claims description 11
- 241000282832 Camelidae Species 0.000 claims description 10
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 10
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 10
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 9
- 102000055228 human IL5 Human genes 0.000 claims description 9
- 208000004187 Immunoglobulin G4-Related Disease Diseases 0.000 claims description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 6
- 201000009961 allergic asthma Diseases 0.000 claims description 6
- 230000000172 allergic effect Effects 0.000 claims description 6
- 208000010668 atopic eczema Diseases 0.000 claims description 6
- 208000024711 extrinsic asthma Diseases 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 5
- 206010014561 Emphysema Diseases 0.000 claims description 5
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims description 5
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 5
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 5
- 206010006451 bronchitis Diseases 0.000 claims description 5
- 208000007451 chronic bronchitis Diseases 0.000 claims description 5
- 208000015768 polyposis Diseases 0.000 claims description 5
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims description 4
- 208000023514 Barrett esophagus Diseases 0.000 claims description 4
- 208000023665 Barrett oesophagus Diseases 0.000 claims description 4
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims description 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 4
- 206010030113 Oedema Diseases 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 230000021615 conjugation Effects 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- 230000002327 eosinophilic effect Effects 0.000 claims description 3
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims description 2
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims description 2
- 108010008177 Fd immunoglobulins Proteins 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 abstract description 22
- 238000010586 diagram Methods 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 63
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 49
- 108010038484 Interleukin-5 Receptors Proteins 0.000 description 44
- 102000010786 Interleukin-5 Receptors Human genes 0.000 description 44
- 210000003979 eosinophil Anatomy 0.000 description 37
- 102000005962 receptors Human genes 0.000 description 35
- 108020003175 receptors Proteins 0.000 description 35
- 102000004127 Cytokines Human genes 0.000 description 34
- 108090000695 Cytokines Proteins 0.000 description 34
- 230000001419 dependent effect Effects 0.000 description 33
- 239000000203 mixture Substances 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 25
- 150000001413 amino acids Chemical class 0.000 description 24
- 230000000694 effects Effects 0.000 description 22
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 238000012360 testing method Methods 0.000 description 20
- 125000000539 amino acid group Chemical group 0.000 description 18
- 108020004999 messenger RNA Proteins 0.000 description 18
- 210000004072 lung Anatomy 0.000 description 17
- 230000011664 signaling Effects 0.000 description 17
- 101150034852 agr2 gene Proteins 0.000 description 16
- 239000013566 allergen Substances 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 229920001184 polypeptide Polymers 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 210000003719 b-lymphocyte Anatomy 0.000 description 13
- 102000003675 cytokine receptors Human genes 0.000 description 13
- 108010057085 cytokine receptors Proteins 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- 238000001543 one-way ANOVA Methods 0.000 description 13
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 13
- 235000002198 Annona diversifolia Nutrition 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 230000001404 mediated effect Effects 0.000 description 12
- 239000012530 fluid Substances 0.000 description 11
- 241000282842 Lama glama Species 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 101000960966 Mus musculus Interleukin-5 Proteins 0.000 description 9
- 230000004663 cell proliferation Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 9
- 238000003780 insertion Methods 0.000 description 9
- 230000037431 insertion Effects 0.000 description 9
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 8
- 108010017511 Interleukin-13 Receptors Proteins 0.000 description 8
- 102100020791 Interleukin-13 receptor subunit alpha-1 Human genes 0.000 description 8
- 101710112663 Interleukin-13 receptor subunit alpha-1 Proteins 0.000 description 8
- 102000015728 Mucins Human genes 0.000 description 8
- 108010063954 Mucins Proteins 0.000 description 8
- 206010070834 Sensitisation Diseases 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 230000008313 sensitization Effects 0.000 description 8
- 206010014950 Eosinophilia Diseases 0.000 description 7
- 102000004559 Interleukin-13 Receptors Human genes 0.000 description 7
- 101001002703 Mus musculus Interleukin-4 Proteins 0.000 description 7
- 208000026935 allergic disease Diseases 0.000 description 7
- 239000012636 effector Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000013595 glycosylation Effects 0.000 description 7
- 238000006206 glycosylation reaction Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 230000004199 lung function Effects 0.000 description 7
- 230000003472 neutralizing effect Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 description 6
- 230000007815 allergy Effects 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 230000016396 cytokine production Effects 0.000 description 6
- 210000003630 histaminocyte Anatomy 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 238000009097 single-agent therapy Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000428 dust Substances 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010003645 Atopy Diseases 0.000 description 4
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 4
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 4
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 description 4
- 102100039881 Interleukin-5 receptor subunit alpha Human genes 0.000 description 4
- 241000282838 Lama Species 0.000 description 4
- 102000043131 MHC class II family Human genes 0.000 description 4
- 108091054438 MHC class II family Proteins 0.000 description 4
- 101100096342 Mus musculus Spdef gene Proteins 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 241001416177 Vicugna pacos Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 229950003468 dupilumab Drugs 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 208000036065 Airway Remodeling Diseases 0.000 description 3
- 206010003557 Asthma exercise induced Diseases 0.000 description 3
- 206010003559 Asthma late onset Diseases 0.000 description 3
- 208000014085 Chronic respiratory disease Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 208000004657 Exercise-Induced Asthma Diseases 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 3
- 108010087819 Fc receptors Proteins 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 3
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 3
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- 101710098691 Interleukin-5 receptor subunit alpha Proteins 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 229960004784 allergens Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000012911 assay medium Substances 0.000 description 3
- 210000003651 basophil Anatomy 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000010250 cytokine signaling pathway Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 208000000884 Airway Obstruction Diseases 0.000 description 2
- 230000010785 Antibody-Antibody Interactions Effects 0.000 description 2
- 208000009657 Aspirin-Induced Asthma Diseases 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 2
- 108010058683 Immobilized Proteins Proteins 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 101710169536 Interleukin-4 receptor subunit alpha Proteins 0.000 description 2
- 102100039897 Interleukin-5 Human genes 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 206010030216 Oesophagitis Diseases 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000238711 Pyroglyphidae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000037446 allergic sensitization Effects 0.000 description 2
- 230000006229 amino acid addition Effects 0.000 description 2
- 238000009175 antibody therapy Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229950000321 benralizumab Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 208000006881 esophagitis Diseases 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 229940046533 house dust mites Drugs 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 108700025647 major vault Proteins 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000005015 mediastinal lymph node Anatomy 0.000 description 2
- 229960005108 mepolizumab Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000003924 normoblast Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229960003254 reslizumab Drugs 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 101100069857 Caenorhabditis elegans hil-4 gene Proteins 0.000 description 1
- 101100230428 Caenorhabditis elegans hil-5 gene Proteins 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000238710 Dermatophagoides Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 235000017274 Diospyros sandwicensis Nutrition 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000746783 Homo sapiens Cytochrome b-c1 complex subunit 6, mitochondrial Proteins 0.000 description 1
- 101000960936 Homo sapiens Interleukin-5 receptor subunit alpha Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101150003028 Hprt1 gene Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 1
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010072089 Interleukin-5 Receptor alpha Subunit Proteins 0.000 description 1
- 102000006760 Interleukin-5 Receptor alpha Subunit Human genes 0.000 description 1
- 241000282852 Lama guanicoe Species 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 206010025280 Lymphocytosis Diseases 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 101001033311 Mus musculus Interleukin-4 receptor subunit alpha Proteins 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 101150014879 RpL13A gene Proteins 0.000 description 1
- 108010011005 STAT6 Transcription Factor Proteins 0.000 description 1
- 102100023980 Signal transducer and activator of transcription 6 Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108010009386 Type I Interleukin-4 Receptors Proteins 0.000 description 1
- 102000009509 Type I Interleukin-4 Receptors Human genes 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241000282840 Vicugna vicugna Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 101100055073 Xenopus laevis agr2-a gene Proteins 0.000 description 1
- 101100055074 Xenopus laevis agr2-b gene Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- 229960000810 binetrakin Drugs 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000010083 bronchial hyperresponsiveness Effects 0.000 description 1
- 210000000233 bronchiolar non-ciliated Anatomy 0.000 description 1
- 239000004044 bronchoconstricting agent Substances 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 230000003435 bronchoconstrictive effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000014564 chemokine production Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 210000000254 ciliated cell Anatomy 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940124446 critical care medicine Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 102000046157 human CSF2 Human genes 0.000 description 1
- 102000048638 human UQCRH Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 210000003111 iliac vein Anatomy 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003550 mucous cell Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 229940109690 nucala Drugs 0.000 description 1
- 208000014055 occupational lung disease Diseases 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000016441 regulation of mucus secretion Effects 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102200081893 rs137854510 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 101150047761 sdhA gene Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 238000010181 skin prick test Methods 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000002966 stenotic effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229950000835 tralokinumab Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229940046536 tree pollen allergenic extract Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 102000042286 type I cytokine receptor family Human genes 0.000 description 1
- 108091052247 type I cytokine receptor family Proteins 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024017576A JP2024063016A (ja) | 2018-02-15 | 2024-02-08 | Ｉｌ－５／ｉｌ－５ｒ、及び、ｉｌ－４／ｉｌ－４ｒ又はｉｌ－１３／ｉｌ－１３ｒに対する組合せアンタゴニスト |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1802487.7A GB201802487D0 (en) | 2018-02-15 | 2018-02-15 | Cytokine combination therapy |
| GB1802487.7 | 2018-02-15 | ||
| PCT/EP2019/053890 WO2019158728A1 (en) | 2018-02-15 | 2019-02-15 | Combined antagonists against il-5/il-5r and either il-4/il-4r or il-13/il-13r |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024017576A Division JP2024063016A (ja) | 2018-02-15 | 2024-02-08 | Ｉｌ－５／ｉｌ－５ｒ、及び、ｉｌ－４／ｉｌ－４ｒ又はｉｌ－１３／ｉｌ－１３ｒに対する組合せアンタゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021513974A true JP2021513974A (ja) | 2021-06-03 |
| JPWO2019158728A5 JPWO2019158728A5 (zh) | 2022-03-09 |
Family
ID=61783635
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543512A Pending JP2021513974A (ja) | 2018-02-15 | 2019-02-15 | Ｉｌ−５／ｉｌ−５ｒ、及び、ｉｌ−４／ｉｌ−４ｒ又はｉｌ−１３／ｉｌ−１３ｒに対する組合せアンタゴニスト |
| JP2024017576A Pending JP2024063016A (ja) | 2018-02-15 | 2024-02-08 | Ｉｌ－５／ｉｌ－５ｒ、及び、ｉｌ－４／ｉｌ－４ｒ又はｉｌ－１３／ｉｌ－１３ｒに対する組合せアンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024017576A Pending JP2024063016A (ja) | 2018-02-15 | 2024-02-08 | Ｉｌ－５／ｉｌ－５ｒ、及び、ｉｌ－４／ｉｌ－４ｒ又はｉｌ－１３／ｉｌ－１３ｒに対する組合せアンタゴニスト |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200399382A1 (zh) |
| EP (1) | EP3752529A1 (zh) |
| JP (2) | JP2021513974A (zh) |
| CN (1) | CN112041342A (zh) |
| AU (1) | AU2019221627A1 (zh) |
| CA (1) | CA3088734A1 (zh) |
| GB (1) | GB201802487D0 (zh) |
| IL (1) | IL276344A (zh) |
| WO (1) | WO2019158728A1 (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202126688A (zh) * | 2019-09-27 | 2021-07-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療遲發性氣喘之方法 |
| WO2021249555A1 (en) * | 2020-06-12 | 2021-12-16 | Beijing Vdjbio Co., Ltd. | Fusion polypeptide |
| CN117903303A (zh) * | 2020-08-20 | 2024-04-19 | 南京融捷康生物科技有限公司 | Il-5的结合分子及其应用 |
| KR20220035655A (ko) * | 2020-09-14 | 2022-03-22 | 아주대학교산학협력단 | 인터루킨-4 수용체 알파 서브유닛과 인터루킨-5 수용체 알파 서브유닛에 동시에 결합하는 이중특이항체 및 이의 용도 |
| CN114605539B (zh) * | 2020-12-09 | 2024-01-02 | 南京融捷康生物科技有限公司 | 人源化的抗IL-4Rα单域抗体及其应用 |
| WO2022150791A2 (en) * | 2021-01-11 | 2022-07-14 | Synthekine, Inc. | Compositions and methods related to il2 receptor binding |
| CN114805572B (zh) * | 2021-01-22 | 2022-12-13 | 上海济煜医药科技有限公司 | 抗原结合蛋白及其应用 |
| CN117999291A (zh) * | 2022-05-23 | 2024-05-07 | 南京融捷康生物科技有限公司 | 一种稳定的抗体制剂 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016113217A1 (en) * | 2015-01-12 | 2016-07-21 | Medimmune Limited | Il-13 binding proteins and uses thereof |
| JP2016523863A (ja) * | 2013-06-21 | 2016-08-12 | サノフィ・バイオテクノロジー | Ｉｌ−４ｒアンタゴニストの投与により鼻茸を処置する方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| KR20220162801A (ko) | 2008-04-11 | 2022-12-08 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| GB2461546B (en) | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
| US9011852B2 (en) * | 2010-04-30 | 2015-04-21 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies |
| GB201707484D0 (en) | 2017-05-10 | 2017-06-21 | Argenx Bvba | Method of preparing ph-dependent antibodies |
-
2018
- 2018-02-15 GB GBGB1802487.7A patent/GB201802487D0/en not_active Ceased
-
2019
- 2019-02-15 CN CN201980025923.3A patent/CN112041342A/zh active Pending
- 2019-02-15 AU AU2019221627A patent/AU2019221627A1/en active Pending
- 2019-02-15 JP JP2020543512A patent/JP2021513974A/ja active Pending
- 2019-02-15 WO PCT/EP2019/053890 patent/WO2019158728A1/en unknown
- 2019-02-15 US US16/966,237 patent/US20200399382A1/en active Pending
- 2019-02-15 EP EP19715814.0A patent/EP3752529A1/en active Pending
- 2019-02-15 CA CA3088734A patent/CA3088734A1/en active Pending
-
2020
- 2020-07-28 IL IL276344A patent/IL276344A/en unknown
-
2024
- 2024-02-08 JP JP2024017576A patent/JP2024063016A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016523863A (ja) * | 2013-06-21 | 2016-08-12 | サノフィ・バイオテクノロジー | Ｉｌ−４ｒアンタゴニストの投与により鼻茸を処置する方法 |
| WO2016113217A1 (en) * | 2015-01-12 | 2016-07-21 | Medimmune Limited | Il-13 binding proteins and uses thereof |
Non-Patent Citations (2)
| Title |
|---|
| J ALLERGY CLIN IMMUNOL., 2018 OCT, VOL.142 NO.4, P.1185-1193, JPN6023008893, ISSN: 0005006478 * |
| 内科, 2016, VOL.118 NO.6, P.1121-1128, JPN6023008892, ISSN: 0005006477 * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB201802487D0 (en) | 2018-04-04 |
| WO2019158728A1 (en) | 2019-08-22 |
| IL276344A (en) | 2020-09-30 |
| JP2024063016A (ja) | 2024-05-10 |
| EP3752529A1 (en) | 2020-12-23 |
| CA3088734A1 (en) | 2019-08-22 |
| AU2019221627A1 (en) | 2020-08-06 |
| CN112041342A (zh) | 2020-12-04 |
| US20200399382A1 (en) | 2020-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021513974A (ja) | Ｉｌ−５／ｉｌ−５ｒ、及び、ｉｌ−４／ｉｌ−４ｒ又はｉｌ−１３／ｉｌ−１３ｒに対する組合せアンタゴニスト | |
| US10815297B2 (en) | Antagonists of IL17C for the treatment of inflammatory disorders | |
| JP6159684B2 (ja) | Ｉｌ−６ｒ関連疾患及び障害の治療のためのｉｌ−６ｒに指向性を有する改善されたアミノ酸配列及びこれを含むポリペプチド | |
| CA2420231C (en) | Antibodies to human il-1.beta. | |
| AU2001295490A1 (en) | Antibodies to human IL-1beta | |
| US20220340654A1 (en) | Antibody capable of binding to thymic stromal lymphopoietin and use thereof | |
| JP7454882B2 (ja) | 抗ヒトインターロイキン－４受容体α抗体及びその調製方法並びに使用 | |
| WO2021093760A1 (zh) | 含有TGF-β受体的融合蛋白及其医药用途 | |
| US20220356239A1 (en) | Il-5 antibody, antigen binding fragment thereof, and medical application therefor | |
| KR20210145187A (ko) | Il-5에 대한 항체를 함유하는 약학적 조성물 및 이의 용도 | |
| US20210332123A1 (en) | Anti-il-25 antibodies and use thereof | |
| WO2016194897A1 (ja) | 肺高血圧症の治療薬及び治療方法 | |
| WO2022117079A1 (zh) | 结合胸腺基质淋巴细胞生成素的抗体及其应用 | |
| EP4104858A1 (en) | Pharmaceutical composition containing anti-il-4r antibody and use thereof | |
| KR20230116857A (ko) | 항 tslp 항체의 약학 조성물 및 이의 용도 | |
| JP2015129187A (ja) | ｈＧＭ−ＣＳＦに結合するモノクローナル抗体および前記抗体を含む医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201210 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20210517 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220214 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220214 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220217 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230307 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20230522 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230606 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230523 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230707 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231010 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240208 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240220 |